Home / Products / Cats & Dogs / Cytopoint / Efficacy

Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT is now approved for the treatment of allergic dermatitis! Learn more
Cytopoint logo

This site is intended for U.S.
animal healthcare professionals

CYTOPOINT® treatment efficacy

CYTOPOINT® treatment efficacy

CYTOPOINT helps relieve itch in dogs within 24 hours while giving skin time to heal after only one injection1

Effective itch relief within one day

  • In a laboratory study, a single injection of CYTOPOINT was shown to significantly decrease IL-31-induced pruritus in dogs within one day of injection and for 28 days2
  • CYTOPOINT decreased pruritus by ≥50% in all dogs at Day 1, and in 95% of dogs at Day 282
Mean pruritus scores of dogs in IL-31-induced pruritus model2*
CYTOPOINT Canine Itch Relief Efficacy Chart
  • Least squares mean (±SE).
  • Day -7 means are arithmetic mean values.
  • Statistically significant (P<0.0001) compared to placebo.
CYTOPOINT was shown to be safe and effective in an independent, real-world study of dogs with allergic dermatitis3*

Success with CYTOPOINT treatment

87.8%

were treatment successes after one injection3†

77%

achieved a PVAS‡ reduction of ≥50%3

MAJORITY
of dogs

showed clinical improvement within 24 hours3§

Success in dogs with all reported types of allergic dermatitis

No significant difference in success between disease types3

82%
of dogs with allergic dermatitis of undetermined cause
WERE TREATMENT SUCCESSES†
  • All 10 dogs with food allergies and atopic dermatitis were treatment successes with CYTOPOINT†
  • All study dogs, regardless of dermatitis type (i.e., allergic or atopic), were likely to be treatment successes†
  • 93.3% (56/60) of large/giant dogs were treatment successes†

Success across patient types

No significant differences in success with CYTOPOINT for3:

Age at onset of allergic signs

Duration of allergic dermatitis symptoms

Age at time of
first administration

  • Adverse events, reported by owners in 8.3% of dogs, were minor and resolved without medical intervention.
  • Treatment success for owner-assessed pruritus control was empirically defined as ≥2 cm reduction in PVAS from baseline on the day of assessment.
  • Owners described their dog’s level of itching by marking a point on a vertical line between extremely itchy and not itchy. Itching includes scratching, biting, licking, chewing and rubbing.4
  • Time until efficacy was known in 68 out of 135 dogs.

Fast, lasting canine atopic itch relief

  • CYTOPOINT starts working in 24 hours, continues working for 4 to 8 weeks* after 1 injection to help reduce pruritus and lesions associated with canine atopic dermatitis1

Percentage of dogs with atopic dermatitis who had successful pruritus relief 1†
CYTOPOINT Canine Itch Relief Efficacy Chart
Mean pet owner-assessed VAS score1
CYTOPOINT VAS Efficacy Score Chart

Defining treatment success

  • Repeat administration every 4 to 8 weeks as needed in individual patients.1
  • Successful canine pruritus relief was defined as a reduction in pruritus score of ≥20 mm on the visual analog scale (VAS). VAS is an owner-assessed scale that measures itch along a continuum from normal dog (no itch) to extremely severe itch, using numbers from 0 to 100. VAS scoring instruments were given to owners, accompanied by explanations of how to record itch based on the behavior of the dog. Owners recorded itch on Days 1, 2, 3, 7 and every 7 days thereafter.1
  • Statistically significant compared to placebo (P≤0.05).
  • Day 0 means are arithmetic mean values.

CYTOPOINT gives damaged skin a chance to heal after 1 injection1

Percentage of patients who had successful improvement in skin condition1*
CYTOPOINT canine skin improvement
Mean veterinarian-assessed CADESI-03 score1
CADESI-03 scores after CYTOPOINT

See Coco’s CYTOPOINT story

Defining treatment success

  • Treatment success was defined as a ≥50% reduction from baseline in skin condition scores as assessed by veterinarians using the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) score. CADESI-03 skin condition assessment consisted of an evaluation of erythema, lichenification, excoriation and self-induced alopecia at 62 body sites.1
  • Statistically significant compared to placebo (P≤0.05).
  • ‡Day 0 means are arithmetic mean values.
CADESI-O3 measures CYTOPOINT efficacy

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc. 2. Data on file, Study Report No. C166R-US-17-180, Zoetis Inc. 3. Souza C, Rosychuk R, Contreras E, et al. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol. 2018. doi: 10.1111/vde.12682. 4. Hill PB, Lau P, Rybnicek J. Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol. 2007:18;301-308.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2018 Zoetis Services LLC. All rights reserved. CYT-00090R4

CONTACT US

1-888-963-8471

We are Mon–Fri, 8:30am–8:00pm ET

email to productsupport@zoetisus.comproductsupport@zoetisus.com

zoetis logo United States flag United States

This site is intended for U.S. Animal Healthcare Professionals.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2019 Zoetis Services LLC. All rights reserved.